These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Role of adjuvant chemotherapy in patients with stage II nonseminomatous germ-cell tumors.
    Author: Motzer RJ, Bosl GJ.
    Journal: Urol Clin North Am; 1993 Feb; 20(1):111-6. PubMed ID: 8381992.
    Abstract:
    Two options exist in the management of pathologic stage II nonseminomatous germ-cell tumors after retroperitoneal lymphadenectomy. First, patients may be followed closely and given three or four cycles of cisplatin-based chemotherapy at relapse. This option is appropriate only if compliance with follow-up is ensured. Second, patients with pathologic stage N2b or N3 disease may be given two cycles of cisplatin-based adjuvant chemotherapy. This approach nearly guarantees a cure but subjects patients who are not destined to have a relapse to chemotherapy. Such management is mandatory in patients who are noncompliant.
    [Abstract] [Full Text] [Related] [New Search]